Repare Therapeutics (NASDAQ:RPTX) Earns Buy Rating from HC Wainwright

Repare Therapeutics (NASDAQ:RPTXGet Rating)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $25.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 155.10% from the stock’s current price.

Other equities analysts have also issued reports about the company. Morgan Stanley dropped their price target on Repare Therapeutics from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Monday, February 27th. Capital One Financial reissued an “overweight” rating and issued a $28.00 price target on shares of Repare Therapeutics in a research note on Friday, January 6th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Repare Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $24.25.

Repare Therapeutics Stock Performance

Shares of RPTX opened at $9.80 on Friday. Repare Therapeutics has a 52-week low of $8.06 and a 52-week high of $18.68. The business’s 50 day moving average price is $11.59 and its two-hundred day moving average price is $13.36. The firm has a market cap of $412.38 million, a PE ratio of -12.56 and a beta of 0.08.

Hedge Funds Weigh In On Repare Therapeutics

Institutional investors have recently modified their holdings of the company. Deutsche Bank AG acquired a new position in shares of Repare Therapeutics during the fourth quarter worth approximately $40,000. UBS Group AG grew its holdings in Repare Therapeutics by 26.3% during the third quarter. UBS Group AG now owns 3,551 shares of the company’s stock worth $43,000 after buying an additional 739 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Repare Therapeutics by 185.8% during the fourth quarter. Wells Fargo & Company MN now owns 3,041 shares of the company’s stock worth $45,000 after buying an additional 1,977 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in Repare Therapeutics during the third quarter worth $113,000. Finally, Lazard Asset Management LLC bought a new stake in Repare Therapeutics during the fourth quarter worth $114,000. 78.19% of the stock is owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile

(Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Featured Stories

Analyst Recommendations for Repare Therapeutics (NASDAQ:RPTX)

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.